IMMP Immutep Limited

+0.04  (+2%)
Previous Close 1.9
Open 1.91
Price To Book 2.73
Market Cap 65572000
Shares 33,800,000
Volume 15,443
Short Ratio
Av. Daily Volume 325,972

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b first data likely due 1Q 2019.
Eftilagimod Alpha - Active Immunotherapy PAClitaxel (AIPAC)
Metastatic breast cancer (MBC)
Phase 1 updated data presented April 2, 2019.
Eftilagimod alpha and Keytruda (TACTI-mel)
Phase 2 dosing of first patient announced March 6, 2019.
Eftilagimod alpha and Keytruda - TACTI-002
Non-small cell lung cancer; Head and neck cancer

Latest News

  1. Immutep Limited (ASX:IMM): Are Analysts Optimistic?
  2. Edison Issues ADR Update on Immutep (IMMP)
  3. Immutep to Host Eftilagimod Alpha Clinical Development Update Global Webcast
  4. Immutep Announces United States Patent Grant for Eftilagimod Alpha in Cancer
  5. Immutep to Present IMP761 Preclinical Results in Global Webcast
  6. Immutep Presents Positive IMP761 Preclinical Results at 14th Congress of European Crohn’s and Colitis Organisation
  7. Immutep Shareholders Have Enjoyed A 52% Share Price Gain
  8. Immutep doses First Patient in TACTI-002 Phase II Trial
  9. Immutep Announces Data from Ongoing TACTI-mel Phase I Clinical Trial in Unresectable or Metastatic Melanoma
  10. The Daily Biotech Pulse: Horizon Pharma Under DoJ Radar, FDA Greenlights J&J's Depression Drug, Endologix Reverse Split
  11. Immutep to Present at Oppenheimer’s 29th Annual Healthcare Conference
  12. Immutep to Present at Upcoming Industry Conferences
  13. Honest Company co-founder Christopher Gavigan has a new, and newly funded, CBD startup called Prima
  14. Immutep Enters Into Clinical Trial Collaboration, Service and Supply Agreement With CYTLIMIC
  15. Immutep Announces US$5.2 Million Financing Led by U.S. Specialist Healthcare Investor, Altium Capital
  16. New Data from Ongoing TACTI-mel Study in Unresectable or Metastatic Melanoma Presented at the 4th Annual ICI Europe Summit
  17. Edison issues ADR update on Immutep (IMMP)
  18. Immutep Presents Positive New Data from Ongoing TACTI-mel Study at Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting
  19. Gaming guide creator Prima Games is shutting down
  20. Operational Update